TSVT - Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? | Benzinga
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.
Revenues increased 1% to $3.43 billion, beating the consensus of $3.29 billion. Total revenues excluding Ronapreve (COVID-19 treatment) reached $3.44 billion, up 14% Y/Y.
In the fourth quarter of 2023, Dupixent global net sales (recorded by Sanofi SA (NASDAQ: SNY)) increased 31% Y/Y to $3.22 billion.
In the fourth quarter of 2023, U.S. net sales ...